News

The interview explores the growing demand for lentiviral vectors, the manufacturing requirements associated with emerging in vivo applications, and the innovation needed to support the next generation of gene therapies.

Natalia Elizalde discusses key hurdles in translating in vivo gene therapies from promise to clinical reality in an IBTV interview

Marie Fertin contributes key perspectives on pseudotyping strategies and in vivo lentiviral vector development.

Natalia Elizalde, PhD, Chief Business Development Officer at VIVEbiotech, shares insights on the evolution of gene therapy and the growing relevance of in vivo lentiviral vector platforms.

Natalia Elizalde shares key insights on flexible and cost-efficient CDMO contracts alongside leading industry experts.

A comprehensive review on the evolution and applications of lentiviral vectors, reinforcing VIVEbiotech’s scientific and technological leadership.

Natalia Elizalde, Chief Business Development Officer, shares expert insight on overcoming CGT manufacturing challenges.

Natalia Elizalde, CBDO at VIVEbiotech, shares key insights in pharmaphorum on the latest advances and ongoing challenges in producing in-vivo lentiviral vectors — a cornerstone technology for the future of advanced therapies.

VIVEbiotech CEO Jon Alberdi featured on the “Molecule to Market” podcast.

Following her participation in Advanced Therapies London, our Chief Business Development Officer’s insights on the evolution of lentiviral vectors were featured in Drug Discovery World.

The initiative, funded by the CDTI and the Ministry of Science and Innovation, promotes innovation in lentiviral vectors through artificial intelligence and DNA biotechnology.

Natalia Elizalde shares insights on the future of cell and gene therapy.

We’re thrilled to announce that our latest research paper entitled “Establishment and Characterization of a Stable Producer Cell Line Generation Platform for the Manufacturing of Clinical-Grade Lentiviral Vectors” has been published in the journal Biomedicines.

Natalia Elizalde, our Chief Business Development Officer at VIVEbiotech, recently shared her expertise with GEN on the increasing demand for lentiviral vectors, of which we are experts at VIVEbiotech.

VIVEbiotech has published a scientific paper in the journal Viruses

VIVEbiotech has participated in a second roundtable in Pharma’s Almanac entitled “How Can (Bio)pharmaceutical Companies Contribute to Improving Global Access to Essential Medications?”.

Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, has contributed to a Pharma’s Almanac’s roundtable discussing how technological advancements are reshaping the roles and capabilities of CDMOs and CROs.

Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, answered some questions for The Medicine Maker around the trends and key topics that were covered throughout American Society of Gene & Cell Therapy´s (ASGCT) annual meeting that took place last May in Baltimore.

Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, participates in a roundtable article by Pharma’s Almanac.

The MAGIC Consortium is proud to announce the participation of Instituto de Medicina Molecular João Lobo Antunes (iMM) in the MAGIC Project.

VIVEbiotech has contributed to a roundtable article in Pharma’s Almanac discussing strategies being employed to accelerate product development and commercialization without compromising quality.

The Ministry of Science, Innovation and Universities in collaboration with the Center for Technological Development and Innovation (CDTI) have selected it as one of the 40 projects that address a challenge that is at the forefront of society and the economy, and which will be funded by €3.8 million.

The project will be undertaken by a public-private consortium formed by VIVEbiotech, Integra Therapeutics and OneChain Immunotherapeutics, the UPF, the IBMB-CSIC and the CIEMAT over the next four years.

At the end of 2023, Scrip Citeline Commercial gave us the opportunity to provide predictions for the year ahead.

Pharma Manufacturing asked Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, about her predictions on therapeutic advances for 2024.

Bárbara Rodríguez-Urretavizcaya, Analytical Development Scientist at VIVEbiotech, will be presenting today at a Gyrolab Technology Seminar.

VIVEbiotech participates in an article in Endpoints News about the challenges facing lentiviral vector production.

On November 28th VIVEbiotech participated in a webinar invited by Xpress Biologics, Polyplus, Sartorius.

Towards the end of last year, Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, was asked about her predictions for 2024 by the Drug Discovery World.

Gurutz Linazasoro, CEO of VIVEbiotech, was elected as a member of the Board of Directors of AseBio, the Spanish Bioindustry Association, at the Ordinary and Extraordinary General Assembly held yesterday.

VIVEbiotech has contributed to a winter roundtable article in Pharma’s Almanac.

Contract Pharma has reached out to Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, for a Q+A session, seeking her expertise on the lentiviral vector market.

VIVEbiotech has been featured in an article in BioPharm International

An article featured by Natalia Elizalde, Chief Business Development Officer at VIVEbiotech, has just been published by European Pharmaceutical Manufacturer.

The Medicine Maker has published an opinion article after interviewing Natalia Elizalde, VIVEbiotech´s Chief Business Development Officer.

In a recent article in BioPharm International, Chris Spivey speaks about different types of viral vectors that are regularly used in gene therapy, each with its advantages and drawbacks.

VIVEbiotech is a CDMO GMP that develops and manufactures lentiviral vectors from early stage to commercial scale. It is currently working on more than 40 international projects in compliance with FDA and EMA regulations, and is manufacturing vectors for companies based in the US, Europe, Asia and Australia. VIVEbiotech is authorized to manufacture lentiviral vectors for both ex-vivo and in-vivo use.

VIVEbiotech participated in the ISCT, International Society for Cell & Gene Therapy´s (ISCT) Annual Meeting took place three weeks ago in beautiful Paris.

Natalia Elizalde was interviewed at the Phacilitate’s Advanced Therapies Week that took place in Miami in January this year.

Natalia Elizalde was video-interviewed by The Medicine Maker during Phacilitate´s Advanced Therapies Week that took place in Miami in January.

Natalia Elizalde has been included in the clinical trial section about the leading annual article series by Scrip alongside a number of leading international figures in the life science industry.

Labiotech.eu interviewed Natalia Elizalde during Phacilitate’s Advanced Therapies Week congress that took place last week in Miami Beach, Florida.

Natalia Elizalde and Naiara Tejados have participated in a Drug Discovery World cell and gene therapy guide that was recently published.

Naiara Tejados, Head of Marketing and Technology Development, has published an article in The Medicine Maker entitled “Know Your Vectors: a 101 on Lentiviral Therapies”.